Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy.
To present pertinent issues involved in radiation safety in radioimmunotherapy with 90Y ibritumomab tiuxetan. Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radiation safety and radioimmunotherapy. Radioimmunotherapy with 90Y ibritumomab tiuxetan is safe and effective in the indicated population, and radiation safety requirements for caregivers and patients are minimal. Yttrium 90 ibritumomab is routinely and safety administered as an outpatient procedure; safety precautions are universal precautions, with the addition of acrylic shielding for the preparation and administration of the radiolabeled dose. Oncology nurses play a key role in the multidisciplinary team. By observing universal precautions, and advising patients to do the same, oncology nurses may facilitate the safe and effective administration of the ibritumomab tiuxetan regimen.